ZNTL · Healthcare
Zentalis Pharmaceuticals Inc
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$255M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About ZENTALIS PHARMACEUTICALS INC
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic…
Who's behind the signal
Every informed buyer we can see on ZNTL, across all three feeds.
Hedge funds · 6
Millennium Management (Englander)
Increased +92%
Tudor Investment (Paul Tudor Jones)
Unchanged
Point72 (Steve Cohen)
Decreased −5%
D.E. Shaw & Co
Decreased −11%
Citadel Advisors
Decreased −12%
AQR Capital Management
Decreased −51%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ZENTALIS PHARMACEUTICALS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
1
Increasing
4
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+92%
0.0% of Millennium Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
—
0.0% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−5%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−11%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−12%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−51%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ZENTALIS PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ZENTALIS PHARMACEUTICALS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订